Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of April 2026, specifically detailing a share repurchase executed on March 31, 2026. The transaction was conducted through BNP Paribas SA as part of GSK's existing buyback programme under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing focuses exclusively on share repurchase activity and capital structure updates. It does not provide revenue, profit, cash flow, or margin data.
- Shares Purchased (March 31, 2026): 340,000 ordinary shares.
- Price Range: Lowest 2,064.00 GBp; Highest 2,086.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,075.26 GBp.
- Total Buyback Since Feb 17, 2026: 16,221,521 ordinary shares.
- Treasury Shares Held: 256,112,615 ordinary shares.
- Shares in Issue (excluding Treasury): 4,060,067,166 ordinary shares.
- Total Voting Rights: 4,060,067,166.
- Treasury Voting Rights Percentage: 6.31%.
Material Changes
Following the March 31, 2026 purchase, the company's treasury share count increased to 256,112,615. Consequently, the percentage of voting rights attributable to treasury shares is now 6.31%. The number of ordinary shares in issue remains 4,060,067,166. No other material financial changes are reported in this filing.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections. Investors are directed to the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2025 for a detailed list of these risks.
Investor Verification Checklist
- Verify the total number of treasury shares held (256,112,615) against the company's latest capitalization table.
- Confirm the 6.31% voting rights threshold for treasury shares for disclosure compliance under FCA rules.
- Review the remaining capacity under the non-discretionary buyback agreement announced on February 17, 2026.
- Check the Annual Report on Form 20-F for 2025 for detailed risk factors referenced in the cautionary statement.